Eiji Seki

1.0k total citations
24 papers, 848 citations indexed

About

Eiji Seki is a scholar working on Molecular Biology, Physiology and Oncology. According to data from OpenAlex, Eiji Seki has authored 24 papers receiving a total of 848 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 10 papers in Physiology and 7 papers in Oncology. Recurrent topics in Eiji Seki's work include Protein Hydrolysis and Bioactive Peptides (16 papers), Biochemical effects in animals (10 papers) and Neuropeptides and Animal Physiology (6 papers). Eiji Seki is often cited by papers focused on Protein Hydrolysis and Bioactive Peptides (16 papers), Biochemical effects in animals (10 papers) and Neuropeptides and Animal Physiology (6 papers). Eiji Seki collaborates with scholars based in Japan, United Kingdom and Somalia. Eiji Seki's co-authors include Katsuhiro Osajima, Toshiro Matsui, Yutaka Osajima, Hiroshi Matsufuji, Masatoshi Nakashima, Terukazu Kawasaki, Masaki Yoshida, Tomohiro Kawasaki, Kei Tamaya and Yutaka OSAJIMA and has published in prestigious journals such as Journal of Agricultural and Food Chemistry, Carbohydrate Research and Journal of Hypertension.

In The Last Decade

Eiji Seki

23 papers receiving 778 citations

Peers

Countries citing papers authored by Eiji Seki

Since Specialization

Citations

This map shows the geographic impact of Eiji Seki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eiji Seki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eiji Seki more than expected).

Fields of papers citing papers by Eiji Seki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eiji Seki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eiji Seki. The network helps show where Eiji Seki may publish in the future.

Co-authorship network of co-authors of Eiji Seki

This figure shows the co-authorship network connecting the top 25 collaborators of Eiji Seki. A scholar is included among the top collaborators of Eiji Seki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eiji Seki. Eiji Seki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effect of Katsuodashi on postprandial blood glucose levels and identification of dipeptidyl peptidase IV inhibitory peptides among its components 2021 ·Clinical Nutrition Open Science ·(unknown), Eiji Seki, (unknown), T. Yamane, Iwao Ohkubo	2
2	Dipeptidyl Peptidase-IV Inhibitory Activity of Katsuobushi-Derived Peptides in Caco-2 Cell Assay and Oral Glucose Tolerance Test in ICR Mice 2020 ·Journal of Agricultural and Food Chemistry ·Eiji Seki, Akihisa Yamamoto, (unknown), T. Yamane, Hideo Satsu, Iwao Ohkubo	16
3	The Anti-hyperglycemic and Dipeptidyl Peptidase IV Inhibitory Activities of Bonito Dashi: Efficacy Testing in Human Subjects 2018 ·Eiji Seki, (unknown), (unknown), (unknown), T. Yamane, (unknown), Iwao Ohkubo, (unknown)	1
4	PS 13-20 ANTI-HYPERTENSIVE PEPTIDE DERIVED FROM KATSUOBUSHI 2016 ·Journal of Hypertension ·Eiji Seki	0
5	Val‐Tyr As A Natural Antihypertensive Dipeptide Can Be Absorbed Into The Human Circulatory Blood System 2002 ·Clinical and Experimental Pharmacology and Physiology ·Toshiro Matsui, Kei Tamaya, Eiji Seki, Katsuhiro Osajima, Kiyoshi Matsumoto, Terukazu Kawasaki	78
6	[Antihypertensive effect and safety evaluation of vegetable drink with peptides derived from sardine protein hydrolysates on mild hypertensive, high-normal and normal blood pressure subjects]. 2002 ·PubMed ·Terukazu Kawasaki, (unknown), Yoichi Fukushima, (unknown), Eiji Seki, Katsuhiro Osajima, (unknown), Toshiro Matsui, Kiyoshi Matsumoto	22
7	Absorption of Val-Tyr with in Vitro Angiotensin I-Converting Enzyme Inhibitory Activity into the Circulating Blood System of Mild Hypertensive Subjects. 2002 ·Biological and Pharmaceutical Bulletin ·Toshiro Matsui, Kei Tamaya, Eiji Seki, Katsuhiro Osajima, Kiyoshi Matsumoto, Terukazu Kawasaki	65
8	Antihypertensive effect of Valyl-Tyrosine, a short chain peptide derived from sardine muscle hydrolyzate, on mild hypertensive subjects 2000 ·Journal of Human Hypertension ·Tomohiro Kawasaki, Eiji Seki, Katsuhiro Osajima, Masaki Yoshida, (unknown), Toshiro Matsui, Yutaka Osajima	196
9	Antihypertensive Effect of Sardine Peptide and Valyl-Tyrosine in Spontaneously Hypertensive Rats. 1999 ·Nippon Eiyo Shokuryo Gakkaishi ·Eiji Seki, Terukazu Kawasaki, Mayumi Yoshida, Katsuhiro Osajima, Kei Tamaya, Toshiro Matsui, Yutaka Osajima	20
10	Angiotensin I Converting Enzyme Inhibitory Activity of The Short Chain Peptides Derived from Various Food Proteins. 1996 ·Nippon Shokuhin Kagaku Kogaku Kaishi ·Eiji Seki, Katsuhiro Osajima, Hiroshi Matsufuji, Toshiro Matsui, Yutaka OSAJIMA	4
11	Angiotensin I Converting Enzyme Inhibitory Peptides Generated from Oligopeptides by Intestinal Mucosa Peptidases 1996 ·Nippon Nōgeikagaku Kaishi ·Eiji Seki, Katsuhiro Osajima, Hiroshi Matsufuji, Toshiro Matsui, Yutaka Osajima	5
12	Val-Tyr, an Angiotensin I Converting Enzyme Inhibitor from Sardines that have Resistance to Gastrointestinal Proteases 1995 ·Nippon Nōgeikagaku Kaishi ·Eiji Seki, Katsuhiro Osajima, Hiroshi Matsufuji, Toshiro Matsui, Yutaka Osajima	29
13	Angiotensin I-converting Enzyme Inhibitory Peptides in an Alkaline Protease Hydrolyzate Derived from Sardine Muscle 1994 ·Bioscience Biotechnology and Biochemistry ·Hiroshi Matsufuji, Toshiro Matsui, Eiji Seki, Katsuhiro Osajima, Masatoshi Nakashima, Yutaka Osajima	209
14	Inhibition of Angiotensin I-converting Enzyme byBacillus licheniformisAlkaline Protease Hydrolyzates Derived from Sardine Muscle 1993 ·Bioscience Biotechnology and Biochemistry ·(unknown), Hiroshi Matsufuji, Eiji Seki, Katsuhiro Osajima, Masatoshi Nakashima, Yutaka OSAJIMA	154
15	Separation and Purification of Angiotensin I Converting Enzyme Inhibitory Peptides from Heated Sardine Meat by Treatment with Alkaline Protease. 1993 ·NIPPON SHOKUHIN KOGYO GAKKAISHI ·Eiji Seki, Katsuhiro Osajima, Toshiro Matsui, Yutaka Osajima	10
16	Studies on immunoadjuvant active compounds. Part XXIX. Synthesis of N-(2-O-(2-acetamido-1,5-anhydro-2,3-dideoxy-D-glucitol-3-yl)-D-lactoyl)-L-alanyl-D-isoglutamine (1-deoxy-MDP) and some of its lipophilic analogs, and their immunoadjuvant activities. 1986 ·Agricultural and Biological Chemistry ·Akira Hasegawa, (unknown), Eiji Seki, Makoto Kiso, Ichiro Azuma	4
17	Chemical Combination of Biologically Active Derivatives ofN-Acetylmuramoyl Dipeptide and Lipid-A, and Their Biological Activities 1986 ·Journal of Carbohydrate Chemistry ·Akira Hasegawa, Eiji Seki, (unknown), (unknown), Makoto Kiso, Hideharu Ishida, Ichiro Azuma	10
18	Studies on immunoadjuvant active compounds. Part XXXI. Synthesis and biological activities of lipophilic derivatives of 1-deoxy-N-acetylmuramoyl-L-alanyl-D-isoglutamine. 1986 ·Agricultural and Biological Chemistry ·Akira Hasegawa, Eiji Seki, Makoto Kiso, Ichiro Azuma	1
19	Reactions of Enolic Biotin Models 1985 ·Bulletin of the Chemical Society of Japan ·Hiroki Kondo, (unknown), Eiji Seki, Junzo Sunamoto	3
20	Synthesis and immunoadjuvant activity of N-[2-O-(2-acetamido-2,3,di-deoxy-6-thio-d-glucopyranose-3-yl)-d-lactoyl]-l-alanyl-d-isoglutamine derivatives 1984 ·Carbohydrate Research ·Akira Hasegawa, Eiji Seki, (unknown), Makoto Kiso, Ichiro Azuma	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact